Oncoinvent reaches halfway point in ovarian cancer trial enrollment

Oncoinvent reaches halfway point in ovarian cancer trial enrollment

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.